BIOPOC Stock Overview
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 2.35 |
| 52 Week High | DKK 2.86 |
| 52 Week Low | DKK 1.81 |
| Beta | 1.46 |
| 11 Month Change | 0% |
| 3 Month Change | -1.26% |
| 1 Year Change | n/a |
| 33 Year Change | -14.86% |
| 5 Year Change | -25.52% |
| Change since IPO | 8.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOPOC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -0.1% |
| 1Y | n/a | -21.1% | 5.5% |
Return vs Industry: Insufficient data to determine how BIOPOC performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BIOPOC performed against the UK Market.
Price Volatility
| BIOPOC volatility | |
|---|---|
| BIOPOC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BIOPOC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIOPOC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 39 | Tony Pare | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| BIOPOC fundamental statistics | |
|---|---|
| Market cap | DKK 528.59m |
| Earnings (TTM) | -DKK 74.95m |
| Revenue (TTM) | DKK 30.51m |
17.3x
P/S Ratio-7.1x
P/E RatioIs BIOPOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOPOC income statement (TTM) | |
|---|---|
| Revenue | DKK 30.51m |
| Cost of Revenue | DKK 10.10m |
| Gross Profit | DKK 20.40m |
| Other Expenses | DKK 95.36m |
| Earnings | -DKK 74.95m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 01, 2023
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 66.88% |
| Net Profit Margin | -245.68% |
| Debt/Equity Ratio | 0% |
How did BIOPOC perform over the long term?
See historical performance and comparison